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ARTICLE
Nicotinamide Phosphoribosyltransferase Attenuates
Methotrexate Response in Juvenile Idiopathic Arthritis
and In Vitro
RS Funk1,2,6,∗, R Singh1,6, L Pramann1, N Gigliotti5, S Islam4, DP Heruth4, SQ Ye4,7, MA Chan5, JS Leeder2,6 and ML Becker2,3
Variability in response to methotrexate (MTX) in the treatment of juvenile idiopathic arthritis (JIA) remains unpredictable and
poorly understood. Based on previous studies implicating an interaction between nicotinamide phosphoribosyltransferase
(NAMPT) expression and MTX therapy in inflammatory arthritis, we hypothesized that increased NAMPT expression would
be associated with reduced therapeutic response to MTX in patients with JIA. A significant association was found between
increased plasma concentrations of NAMPT and reduced therapeutic response in patients with JIA treated with MTX. Inhibition
of NAMPT in cell culture by either siRNA-based gene silencing or pharmacological inhibition with FK-866 was found to result
in a fourfold increase in the pharmacological activity of MTX. Collectively, these findings provide evidence that NAMPT inhibits
the pharmacological activity of MTX and may represent a predictive biomarker of response, as well as a therapeutic target, in
the treatment of JIA with MTX.
Clin Transl Sci (2016) 9, 149–157; doi:10.1111/cts.12399; published online on 11 May 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Response to MTX in the treatment of JIA remains highly
variable and continues to be unpredictable.
WHAT QUESTION DID THE STUDY ADDRESS?
✔ We hypothesized that NAMPT is an important biomarker
of response to MTX.
WHAT THIS STUDY ADDS TO OUR CURRENT KNOWL-
EDGE?
✔ These findings demonstrate a relationship between ele-
vated NAMPT levels and failure to respond to MTX that
seems to result from a biochemical interaction through
which NAMPT modifies the pharmacological activity of
MTX.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE?
✔ This work may lead to: (1) the use of NAMPT as
a predictive biomarker of response to MTX, and (2) a
therapeutic approach utilizing pharmacological inhibitors
of NAMPT to potentiate the pharmacological activity of
MTX.
Methotrexate (MTX) therapy continues to be a cornerstone in
the treatment of juvenile idiopathic arthritis (JIA). However, in
the age of early and aggressive disease control, MTX therapy
is mired by a delayed onset of action and a highly variable
and unpredictable response profile that makes it the focus
of individualized approaches to therapy.1 Understanding pre-
dictors of optimal or poor response toMTX holds the promise
of more streamlined therapy in JIA. This could include more
rapid initiation or avoidance of the next tier biologic thera-
pies, and their associated costs and risks.
In rheumatoid arthritis (RA) the adipocytokine nicoti-
namide phosphoribosyltransferase (NAMPT), also commonly
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referred to as pre-B-cell colony-enhancing factor and vis-
fatin, has been found at elevated concentrations in the
plasma and synovial fluid of patients with RA, has been
associated with disease activity, and has been found to be
predictive of treatment response.2–10 These findings have
supported a role for NAMPT as both a drug target and a
biomarker in RA, but the role of this adipocytokine in the JIA
population is yet to be established.11,12 Plasma NAMPT lev-
els in a cross-sectional group of patients with JIA were found
by our group to be higher in patients with active disease
and lower in patients actively treated with MTX therapy.13
Although these findings suggest that NAMPT is associated
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with disease activity and MTX response in JIA, there remains
a need for evaluation of NAMPT levels in a prospective cohort
of patients with JIA treatedwithMTX tomore fully understand
the relationship of this adipocytokine with disease activity
and drug response.
Identified and cloned based on its role in stimulating pre-
B-cell colony formation, NAMPT is a ubiquitously expressed
multifunctional protein that functions as both a cytosolic
enzyme in the nicotinamide adenine dinucleotide (NAD) sal-
vage pathway and as a secreted plasma protein that func-
tions in the regulation of inflammation and metabolic activ-
ity, resulting in its designation as an adipocytokine.14–16
As a result of its role in NAD biosynthesis, NAMPT has
been the target of several drug development programs and
has resulted in the discovery of a number of highly potent
inhibitors of its enzymatic activity, including FK-866 and
GMX1778. NAMPT has been reported to stimulate CD14+
monocytes, promote the motility of leukocytes and synovial
fibroblasts from patients with RA, activate the transcrip-
tion factors NF-kB and AP-1, induce the production of var-
ious cytokines including interleukin (IL)-1Ra, IL-1β, TNFα,
and IL-6, and to be induced by cytokines, including IL-1β
and IL-6.17–23 Despite the established proinflammatory role
of NAMPT, the mechanism through which it mediates these
effects remains controversial. Early studies suggested bind-
ing of extracellular NAMPT to the insulin receptor as a
basis for its activity, however, these studies have since been
retracted and no specific extracellular receptor has been
identified to date.24 The presence of an NAMPT receptor sig-
naling pathway has also been supported by the induction of
IL-6 by NAMPT in the presence of the inhibitor of NAMPT
enzymatic activity FK-866.25 In contrast, the role of NAMPT
enzymatic activity in the pathogenesis of inflammatory arthri-
tis has been supported by studies that demonstrated the
role of cellular NAD regulation in lymphocyte development
and activation.14,26 This has been supported further by stud-
ies in the collagen-induced arthritis mouse model that have
found inhibition of NAMPT by either FK-866 or siRNA-based
gene-silencing inhibits leukocyte activation and infiltration,
cytokine production, and overall disease progression.23,27
Further supporting the role of NAMPT enzyme activity in
disease progression, depletion of NAD levels in circulating
leukocytes has been associated with the efficacy of FK-866
in the collagen-induced arthritis mouse model.28
In addition to the role of NAMPT in the pathogenesis of
inflammatory arthritis, a recent study has found that inhi-
bition of NAMPT with GMX1778 results in the depletion of
cellular NAD and enhances the pharmacologic activity of
the antifolate pemetrexed.29 Similar to pemetrexed, MTX is
also an antifolate, and therefore suggests that reductions in
NAMPT expression may potentiate the pharmacologic activ-
ity ofMTX. Although a relationship between elevated baseline
NAMPT levels and increased long-term disease progression
in patients with RA has been demonstrated, the possibility
that variation in NAMPT activity can affect the pharmacologic
activity of MTX has not been evaluated.6
This study evaluates plasma concentrations of NAMPT
in a prospective cohort of patients with JIA over 6 months
after the initiation of MTX to determine the relationship
between circulating NAMPT levels and therapeutic response.
Mechanism-based studies using a cellular model to measure
the activity of MTX were conducted to further evaluate the
pharmacological interaction between NAMPT and MTX.
METHODS
Study design and patients
Patient samples and data were collected from an ongoing
single-center prospective study of patients with JIA started
on standardized MTX dosing (15 mg/m2/week) and followed
over 6 months. Because of a national shortage in MTX for
injection during this study, patients were treated with either
oral (n = 29) or subcutaneous (n = 37) MTX depending on
when they were enrolled. After 3 months on therapy, non-
responders to MTX monotherapy were permitted the addi-
tion of an anti-tumor necrosis factor alpha (TNFα) agent if
deemed clinically necessary. The study was approved by the
Children’s Mercy Hospital institutional review board. Written
informed consent/assent was obtained before the inclusion
of each study participant and collection of patient samples.
NAMPT, IL-1α, IL-1β, IL-1Ra, IL-6, and TNFα concentra-
tions were measured in plasma samples collected before the
initiation of MTX therapy, and after 3 and 6 months after
the initiation of MTX. Erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP), active joint count (AJC), limited joint
count, patient/parent global assessment of overall well-being
visual analogue scale (PT-VAS), physician global assessment
of disease activity (MD-VAS), and Childhood Health Assess-
ment Questionnaire (CHAQ) scores were determined at each
visit. Clinical response was determined by the American
College of Rheumatology pediatric response criteria (ACR
Pedi) and the 71-joint count Juvenile Arthritis Disease Activity
Score (JADAS) after 3 and 6 months on therapy.
Cell lines and reagents
A549 human lung carcinoma cells (catalog no. CCL-185)
were purchased from ATCC (Manassas, VA) and grown in
DMEM (catalog no. 11995-065) supplemented with 10%
fetal bovine serum (catalog no. 03-600-511), 100 U/mL peni-
cillin, and 100 U/mL streptomycin (ThermoFisher Scientific,
Waltham, MA). Cells were maintained at 37°C in a 5% CO2
controlled incubator and were passaged every 3 to 4 days
at approximately 80% confluence. Resazurin sodium salt
(ThermoFisher Scientific) was resuspended at 0.16 mg/mL
in pH 7.4 phosphate-buffered saline (PBS) and passed
through a 0.2 μm syringe filter. Human NAMPT-specific
carboxyl-terminal enzyme immunoassays (catalog no. EK-
003-80) were purchased from Phoenix Pharmaceuticals
(Burlingame, CA). High performance liquid chromatography
purified NAMPT siRNA (sense: 5′-CCACCCAACACAAGC
AAAGUUUAUU-3′) and scrambled control siRNA (sense:
5′-CCACAACAACAAACGUUGAUCCAUU-3′) were custom
synthesized (ThermoFisher Scientific). Multiplex human
cytokine magnetic bead panels for the detection of IL-1α, IL-
1β, IL-1Ra, IL-6, and TNFα (MILLIPLEX MAP, HCYTOMAG-
60K) were purchased from EMD Millipore (Darmstadt,
Germany).
NAMPT and cytokine analysis
Blood samples collected in EDTA tubes were immediately
processed by centrifugation at 800 ×g for 10 min at room
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temperature. Plasma samples were collected and immedi-
ately stored at -80°C before analysis, and were subjected
to a single freeze/thaw cycle. Samples were thawed on ice
and maintained at 4°C for a maximum of 48 h before analy-
sis. NAMPT concentrations were determined in duplicate by
enzyme immunoassay following the manufacturer’s protocol
and analyzed using a BioTek Synergy HT microplate-reader
(BioTek, Winooski, VT) equipped with Gen5 data analysis
software. The average coefficient of variation for all samples
analyzed was 8.4%. Plasma concentrations of IL-1α, IL-1β,
IL-1Ra, IL-6, and TNFα were determined in duplicate by mul-
tiplex analysis using the manufacturer’s protocol. Samples
were analyzed on a Luminex multiplex-reader (Luminex Cor-
poration, Austin, TX) and the resulting average coefficient of
variation for the analytes were 14.7%, 18.4%, 17.5%, 16.8%,
and 12.0%, respectively.
NAMPT inhibition
For each well of a six-well plate, 250 pmoles of siRNA
and 5 μL of Lipofectamine 2000 (ThermoFisher Scientific)
were each added to 250 μL of Opti-MEM reduced serum
media (ThermoFisher Scientific) for 5 min at room temper-
ature before mixing and incubating at room temperature for
20 min, and then added to 1.5 mL of antibiotic-free growth
media containing 2.5× 105 cells. Volumes and densities were
scaled to 5 × 103 cells per well for 96-well plate assays. After
24 h, transfection media was replaced with normal growth
media and maintained for an additional 72 h under normal
culture conditions before analysis. NAMPT enzymatic activ-
ity in cells was inhibited by adding 2.5 nM FK-866.
NAMPT expression and function
Western blot analysis was performed as described
previously.30 Briefly, cell lysate protein was quantified
using the Micro BCA Protein Assay Kit (ThermoFisher Scien-
tific). Protein (20 μg) from each sample was then subjected
to 10% SDS-polyacrylamide gel electrophoresis and trans-
ferred to PVDF membranes (EMD Millipore, Billerica, MA).
The membranes were blocked with 5% nonfat dry milk in
PBS containing 0.1% Tween 20 (TBS-T) at room temperature
for 1 h and then incubated at 4°C overnight with primary
antibody (anti-NAMPT antibody,1:4000). After washing three
times for 10 min with TBS-T, the membrane was incubated
with horseradish-peroxidase-linked goat anti-rabbit sec-
ondary antibody (Santa Cruz Biotechnology, Dallas, TX) at
room temperature for 1 h. The blots were visualized with the
Pierce ECL Western blot detection reagent (ThermoFisher
Scientific). Total cellular NAD content was measured using
a colorimetric enzyme-linked microplate assay (catalog no.
600480) available from Cayman Chemical Company (Ann
Arbor, MI). The assay was conducted in a 96-well plate
format following the manufacturer’s protocol.
Cellular viability
A549 cells seeded at 5 × 103 cells per well in optically clear
black-walled 96-well plates were treated with MTX at con-
centrations up to 100 μM for up to 120 h. To each well con-
taining 100 μL of growth medium, 20 μL of 0.16 mg/mL reza-
surin was added and incubated for 4 h at 37°C and 5% CO2.
The plate was protected from light and allowed to cool to
room temperature for 10 min before reading. Fluorescence
signal was measured for each sample using a BioTek Cyta-
tion 3 multimode plate reader equipped with scanning exci-
tation and emission monochromators set at an excitation
and emission of 560 nm and 590 nm, respectively. Back-
ground signal was subtracted and percent viability was deter-
mined by normalizing fluorescence signal to untreated cells.
Cellular protein content and cell nuclei counting were used
as secondary measures of cellular viability. Protein content
was quantified using the Micro BCA Protein Assay Kit (Ther-
moFisher Scientific) and nuclei were stained with Hoechst
33342 (BD Biosciences, Franklin Lakes, NJ) and counted
using Gen5 image analysis software on a BioTek Cytation
3 equipped with a DAPI filter cube and a 4× objective.
The resulting log dose-response curves were fit to a four-
parameter logistic equation using SigmaPlot v12.5 (Systat
Software, San Jose, CA) and the concentrations resulting in
half maximal inhibition (IC50) are reported. All experiments
were conducted in triplicate unless otherwise noted.
Statistical analysis
Treatment effects on measured variables in the patient sam-
ples were assessed by nonparametric testing including the
Wilcoxon rank-sum test or paired analyses via the Wilcoxon
signed-rank test using JMP software v11 (SAS Institute,
Cary, NC). Associations between continuous variables were
assessed by Spearman’s rank correlation analysis. Data in
the cell-based studies were compared by unpaired Student’s
t test analysis.
RESULTS
Patient clinical and laboratory findings
A participant flow diagram and the individual patient demo-
graphics for patients included in this study are presented
in Figure 1 and Table 1, respectively. Seventy-six percent
of patients with baseline samples had available samples at
3 months and 50% had available samples at 6 months with
the majority of loss due to lack of sample availability because
of inadequate sample volume or because the patient had not
yet reached the subsequent time point. Baseline NAMPT lev-
els were lower among patients with unavailable samples at 3
or 6 months, as compared with those with samples for all vis-
its (median [interquartile range {IQR}]: 10.1 [6.8, 12.5] vs. 11.8
[9.2, 18.2] ng/mL; p = 0.04). However, because of the variety
of reasons for lack of sample availability it is difficult to draw
any conclusions based on this observation. Only 15% of
the observed attrition resulted from therapeutic nonresponse
and no difference in NAMPT levels was observed in this
group compared with those who continued in the study. Con-
sistent with the greater JIA population, the patients enrolled
in this study were predominately female. Statistically signifi-
cant reductions in all individual measures of disease activity
were observed over the treatment period corresponding to
significant reductions in composite JADAS scores after initi-
ation of therapy and 85% of patients meeting ACR Pedi 30
response criteria by 6 months.
Baseline NAMPT levels and disease activity
Pretreatment plasma concentrations of NAMPT spanned
a 14-fold range between 4.2 and 58.9 ng/mL and were
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Figure 1 Flow diagram of participants with plasma samples available for nicotinamide phosphoribosyltransferase (NAMPT) analysis at
their baseline, 3-month, and 6-month clinic visits. Gray boxes indicate participants for which samples at the subsequent clinic visit were
unavailable for analysis.
Table 1 Patient demographics and clinical data before the initiation of MTX
(0 month), and after 3 and 6 months of therapy
Patient characteristics
Visit, months 0 3 6
No. of patients 66 51 34
Gender, female, no. (%) 48 (73) 33 (65) 22 (65)
Age, y, median [IQR] 11.5 [5.4, 14.4] 10.9 [5.3, 13.8] 10.3 [5.5, 13.9]
ESR, mm/h 16 [9, 35] 9 [7, 21]*** 8 [7, 15]***
CRP, mg/L 0.7 [0.5, 1.8] 0.5 [0.5, 1.3]* 0.5 [0.5, 0.6]*
AJC 5 [2, 13] 3 [1, 7]*** 1 [0, 5]***
PT-VAS 6 [3, 8] 2 [0.8, 4]*** 1 [0.5, 4]***
MD-VAS 5 [3, 7] 2 [0, 4]*** 1 [0, 2.5]***
CHAQ 0.5 [0.1, 1.4] 0.12 [0, 0.66]*** 0 [0, 0.25]***
JADAS 19 [12, 30] 7 [4, 16.5]*** 5 [2, 10.15]***
ACR Pedi <30, no. (%) – 15 (29) 5 (15)
ACR Pedi >30, no. (%) – 36 (71) 29 (85)
ACR Pedi >50, no. (%) – 27 (53) 27 (79)
ACR Pedi >70, no. (%) – 14 (27) 18 (53)
ACR Pedi, American College of Rheumatology pediatric response criteria;
AJC, active joint count; CHAQ, Childhood Health Assessment Questionnaire;
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquar-
tile range; JADAS, 71-joint count Juvenile Arthritis Disease Activity Score;
MD-VAS, physician global assessment of disease activity visual analogue
scale; PT-VAS, physician global assessment of disease activity visual ana-
logue scale.
*p < 0.05; **p < 0.01; ***p < 0.001 by paired Wilcoxon signed-rank testing.
found to be positively associated with plasma markers of
inflammation including: CRP (ρ = 0.27; p = 0.03), IL-1α (ρ
= 0.40; p = 0.002), IL-1β (ρ = 0.27; p = 0.03), IL-1Ra (ρ =
0.68; p < 0.0001), IL-6 (ρ = 0.39; p = 0.002), and TNFα (ρ
= 0.27; p = 0.03). Baseline plasma NAMPT levels were not
found to be associated with JADAS scores, or any of the
other individual clinical measures of disease activity. NAMPT
levels were found to be lower in girls compared with boys
(median [IQR]: 10.3 [7.6, 10.8] vs. 13.7 [10.8, 18.8] ng/mL;
p = 0.04), but were not found to vary significantly by disease
subtype, age, weight, or body mass index. No significant
Figure 2 Plasma nicotinamide phosphoribosyltransferase
(NAMPT) concentrations in juvenile idiopathic arthritis (JIA) after
initiation of methotrexate (MTX). NAMPT concentrations were
measured in plasma samples obtained from patients with JIA
before the initiation of MTX therapy and after 3 and 6 months
of therapy. Data points and representative box and whisker
plots are shown for each time point. Changes in NAMPT values
were evaluated by matched pair analysis using the Wilcoxon
signed-rank test and the resulting p values are provided.
differences in baseline demographics or disease activity were
observed between participants with samples for all visits and
those who did not have available 3- or 6-month samples.
No association between NAMPT levels and erythrocyte
concentrations of MTX or its metabolites were observed.
Effect of MTX on NAMPT levels
Plasma concentrations of NAMPT were measured before the
initiation of MTX therapy and at 3 and 6 months of therapy
(Figure 2). No significant change in plasma NAMPT con-
centrations were observed after the initiation of MTX, as
determined by either paired or unpaired analysis. Changes
in NAMPT concentrations from baseline over the treatment
period were not found to be significantly different between
responders and nonresponders based on the ACR Pedi
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response criteria and did not correlate with changes in
JADAS scores (JADAS) at either 3 or 6 months.
NAMPT levels and therapeutic response in JIA
NAMPT levels at 3 and 6 months were assessed for their
association with clinical response at these two time points.
The relationship between NAMPT levels and changes in each
individual measure of disease activity and inflammation is
provided in Supplementary Table S1. The primary measures
of clinical response for this study were the ACR Pedi cri-
teria and corresponding changes from baseline in JADAS
(JADAS). Although NAMPT levels at 3 months were not
found to be associated with JADAS, lower NAMPT lev-
els were found to be significantly associated with a greater
reduction in active joint count (AJC) from baseline (ρ =
0.32; p = 0.021). Using ACR Pedi response criteria, elevated
3-month NAMPT levels were observed in patients defined
as nonresponders by ACR Pedi 50 criteria compared with
responders (median [IQR]: 12.8 [9.95, 17.6] ng/mL vs. 9.28
[7.54, 14.5]; p = 0.035).
At 6 months, reductions in disease activity by JADAS
were found to be associated with reduced NAMPT levels
measured at 6 months and were primarily driven by an asso-
ciation of NAMPT levels with AJC (Figure 3). In line with the
lack of change observed in NAMPT levels over the treatment
period, it was also found that lower NAMPT levels measured
at baseline were associated with improved response to ther-
apy, as represented by a positive association with AJC at
6 months (ρ = 0.34; p = 0.04).
In concordance with the observed associations with
JADAS, elevated NAMPT concentrations were associated
with nonresponse by ACR Pedi 30 at 6 months (Figure 4b).
Similarly, elevated baseline NAMPT levels were associated
with nonresponse by ACR Pedi 30 and ACR Pedi 50 at
6 months (Figure 4a).
Reduced NAMPT expression potentiates the
pharmacological activity of MTX
Although the pharmacological basis of MTX activity in JIA
remains controversial, the antiproliferative activity of MTX is
believed to represent a primary mechanism of therapeutic
efficacy.31,32 To investigate the role of NAMPT on the phar-
macologic activity of MTX, NAMPT expression was inhibited
in the A549 cell line by siRNA-based silencing of NAMPT.
NAMPT levels were assessed in triplicate byWestern blotting
and remained undetectable in the siRNA transfected cells for
at least 96-hours (Figure 5a). The NAMPT antibody consis-
tently yielded triplet bands that made verification of knock-
down uncertain; therefore, recombinant NAMPT (rNAMPT)
was loaded on the first lane suggesting that the bottom band
of the triplet represents NAMPT. NAMPT knockdown was
verified by measuring cellular NAD levels and NAMPT siRNA
caused an 87% reduction in cellular NAD content consis-
tent with reduced NAMPT expression (Figure 5b). Despite
the marked reduction in NAMPT and NAD levels, no change
in cell viability was observed after NAMPT knockdown
(Figure 5c). Nuclear counting by fluorescence microscopy
using Hoechst 33342 and protein measurements by BCA
analysis supported these findings and actually demonstrated
an increase in cell number and protein content in cells treated
Figure 3 Association between plasma nicotinamide phosphori-
bosyltransferase (NAMPT) concentrations and clinical improve-
ment in disease activity. Linear regression plots of 6-month plasma
NAMPT concentrations vs. changes in (a) Juvenile Arthritis Dis-
ease Activity Score (JADAS) scores and (b) active joint count (AJC)
in patients with juvenile idiopathic arthritis (JIA) over the 6-month
treatment period. Spearman’s rank correlation coefficients (ρ) and
the resulting p values are presented.
with NAMPT siRNA (Supplementary Figure S1). Compared
to the scrambled siRNA control, knockdown of NAMPT
resulted in an approximately fourfold reduction in the con-
centration of MTX resulting in half-maximal inhibition of cell
growth (IC50; mean ± SD: 82.8 ± 3.3 vs. 21.6 ± 2.4 nM;
p < 0.0001; Figure 5d). NAMPT knockdown was also found
to result in an increase in the growth inhibitory capacity
of MTX, as illustrated by the difference in cell viability at
100 μM MTX (mean ± SD: 82.8 ± 1.6% vs. 58.7 ± 6.0%;
p = 0.002). Measurement of cell viability using the Hoechst
33342 nuclear staining method and the BCA protein con-
tent assay yielded a similar four to fivefold reduction in IC50
values for MTX after NAMPT knockdown (Supplementary
Figure S1).
Chemical inhibition of NAMPT potentiates
the pharmacological activity of MTX
To further confirm the role of NAMPT on the pharmacologi-
cal activity of MTX, the competitive inhibitor of NAMPT enzy-
matic activity FK-866 was evaluated for its effect on MTX-
mediated growth inhibition in the A549 cell line. After the
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Figure 4 Relationship between plasma nicotinamide phosphoribosyltransferase (NAMPT) concentrations and clinical improvement by
American College of Rheumatology pediatric response criteria (ACR Pedi) scoring. Plasma NAMPT levels at (a) baseline and (b) 6 months
were compared between patients failing to respond to therapy (i.e., nonresponse) and those responding to therapy (i.e., response) based
on ACR Pedi response criteria. Data points and representative box and whisker plots are shown for ACR Pedi 30, 50, and 70 responses as
assessed after 6 months of therapy. NAMPT concentrations were compared between groups as indicated using the Wilcoxon rank-sum
test and the resulting p values are provided.
treatment procedure previously outlined for the interaction
between the NAMPT inhibitor GMX1778 and pemetrexed,
A549 cells were pretreated for 48 h with MTX before the
addition of 2.5 nM FK-866 for an additional 72 h.29 FK-866
at 2.5 nM was chosen as the maximum tolerated dose and
resulted in less than a 10% reduction in cell viability (mean ±
SD: 91 ± 4% viability). Similar to NAMPT knockdown, FK-
866 treatment resulted in a greater than fourfold reduction in
the IC50 for MTX (63.4 ± 2.7 vs. 13.5 ± 0.9 nM; p < 0.0001;
Figure 6). In agreement with the NAMPT knockdown stud-
ies, it was found that FK-866 caused a significant increase
in the growth inhibitory capacity of MTX, as illustrated by the
difference in cell viability at 100 μM MTX (86.6 ± 0.7% vs.
60.5 ± 1.5%; p < 0.0001).
DISCUSSION
These findings are the first prospective evaluation of the
relationship between MTX therapy and circulating concen-
trations of NAMPT in JIA. Despite 85% of patients meet-
ing the ACR Pedi 30 response criteria at 6 months, NAMPT
concentrations failed to change significantly after the initia-
tion of MTX. Consistent with the coregulation of NAMPT and
inflammatory cytokines, increased NAMPT levels at baseline
were associated with increased plasma levels of IL-1α, IL-
1β, IL-1Ra, IL-6, and TNFα. However, NAMPT levels were not
found to be significantly associated with baseline measures
of disease activity. Although these findings contradict many
of the studies in RA, these findings are not unprecedented. A
study of the 6-month response in patients with RA similarly
failed to find an association between NAMPT levels and dis-
ease activity, and failed to observe a change in NAMPT lev-
els over the study period.33 Similarly, a study in patients with
severe RA treated with infliximab found that NAMPT levels
were not associated with disease activity and did not change
in response to therapy.34 The failure to observe any signif-
icant reduction in NAMPT over the study period does not
necessarily lessen the importance of NAMPT in the patho-
genesis of JIA, as MTX therapy may target the disease pro-
cess downstream of NAMPT. However, it does suggest that
MTX itself does not modify NAMPT expression as a basis for
its pharmacological activity, as suggested by our previous
findings.13 Similarly, the inability to correlate disease activity
and response with changes in NAMPT levels greatly limits the
potential utility of monitoring NAMPT as a reactive biomarker
of response.
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Figure 5 Effect of reduced cellular nicotinamide phosphoribosyltransferase (NAMPT) expression on the pharmacological activity of
methotrexate (MTX). A549 cells were treated with either siRNA targeting NAMPT mRNA or a scrambled control siRNA and evaluated
after 96 hours for differences in (a) NAMPT expression by Western blot analysis, (b) intracellular nicotinamide adenine dinucleotide (NAD)
levels, (c) cell viability measured as resorufin relative fluorescence units (RFUs), and (d) sensitivity to the growth inhibitory effects of MTX.
Results from a single experimental evaluation including three independent replicates are presented here along with the resulting mean
± SD. The Western blot is representative of three independent experimental evaluations and the MTX growth inhibitory response data is
representative of four independent experimental evaluations.
Figure 6 Effect of chemical inhibition of nicotinamide phospho-
ribosyltransferase (NAMPT) on the pharmacological activity of
methotrexate (MTX). Cell viability was determined in A549 cells
treated for 48 h with MTX before the addition of 2.5 nM FK-866
or vehicle control for an additional 72 h. Data points represent the
mean ± SD of viability measurements conducted in a single exper-
iment with three independent replicates.
The observation that increased NAMPT concentrations,
which seem to be stable over the treatment period, are
associated with response failure suggests that NAMPT
may remain a useful predictive biomarker for therapeutic
response. A similar observation has been made in patients
with RA, in which baseline plasma NAMPT levels predicted
long-term disease progression.6 These findings suggest that
higher pretreatment NAMPT concentrations may subse-
quently identify patients who are more inclined to fail MTX,
which could result in earlier intervention with the next tier of
biologic therapies, avoiding unnecessary delays in adequate
therapy. Significant overlap was observed between respon-
ders and nonresponders in our study and therefore would
limit its utility as a single discriminatory biomarker of nonre-
sponse, but perhaps, in the future, may be able to be com-
bined with other markers of response to develop algorithms
to predict drug response early in therapy.
Last, these data support the role of NAMPT as a modi-
fier of the pharmacologic activity of MTX. Inhibition of trans-
lation of NAMPT mRNA through siRNA gene-silencing and
pharmacological inhibition of NAMPT enzyme activity both
resulted in a similar increase in sensitivity to the growth
www.wileyonlinelibrary/cts
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inhibitory activity of MTX. These findings support the hypoth-
esis that NAMPT modifies the pharmacological response to
MTX through its enzymatic activity, and not through recep-
tor signaling pathways. The previous study of pemetrexed
and the NAMPT inhibitor GMX1778 found that pharmaco-
logic inhibition of NAMPT resulted in the depletion of cellu-
lar NAD that was further exacerbated by activation of poly
(ADP-ribose) polymerase (PARP) by pemetrexed resulting in
depletion of the cellular NAD pool and enhanced sensitiv-
ity to pemetrexed.29 Similar to pemetrexed, MTX has also
been found to activate PARP in animal models and in iso-
lated leukocytes.35,36 In agreement with the role of PARP in
the pharmacological activity of MTX, supplementation with
the NAMPT substrate and PARP inhibitor, nicotinamide has
been found to inhibit the hepatotoxic activity of MTX and pro-
mote its efficacy in a mouse model.37,38 Additional interact-
ing pathways for NAD metabolism and MTX have also been
suggested in metabolomic studies that have found inhibi-
tion of NAMPT affects purine biosynthesis, as several steps
of purine and pyrimidine biosynthesis require NAD and its
intermediates.39 The fact that MTX targets enzymes in the
purine and pyrimidine biosynthesis pathway as a component
of its pharmacological activity further links NAMPT to the
known biologic effects of MTX.40 Although the biochemical
mechanism through which NAMPT affects the pharmacolog-
ical activity of MTX remains unclear at this point, these finding
suggest that reduced NAMPT activity is associated with an
increase in the activity of MTX, and may support pharmaco-
logic inhibition of NAMPT as a means of enhancing clinical
response to MTX. To date, no in vivo studies have evaluated
the combination of MTX and NAMPT inhibition. However,
based on these findings the combination would be expected
to result in synergism. Whether the synergism would be lim-
ited to drug efficacy, or would also result in enhanced toxic-
ity, is difficult to assess based on these data. The targeting
of lymphocytes by both NAMPT inhibitors andMTX suggests
that combination would result in increased efficacy, however,
the basis for toxicity of these agents is less clear and may
display a similar synergism.26,31,32
With the paucity of biomarkers in children, resulting from
many of the same problems that have historically plagued
pediatric drug development, there remains a need to identify
clinical biomarkers in the pediatric population to help guide
drug therapy. Therefore, despite the incomplete understand-
ing of the biochemical basis for the observed relationship
between NAMPT and MTX, these results highlight the poten-
tial role of plasma NAMPT levels as a clinical biomarker in
predicting therapeutic response to MTX. Most importantly,
the ability of pretreatment NAMPT levels to predict future
response to MTX may fulfill a critical need in the treatment
regimen of JIA. The identification of poor responders to MTX,
a priori, allows clinicians to choose potentially more effective
therapies at the onset of treatment, minimizing the delay in
achievement of disease control and further optimizing long-
term outcomes in JIA.
Future studies are needed to understand more fully the
mechanism through which NAMPT modifies the pharmaco-
logical activity of MTX and the role of NAMPT as a biomarker
of therapeutic response to MTX in JIA. Such an understand-
ing may present the opportunity to target NAMPT and related
biochemical pathways in drug development for the treatment
of JIA and further support its role as a predictive clinical
biomarker in the treatment of JIA.
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